Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | PREP | P48147 | 4/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6761192 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL10106331 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL10106427 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL641026 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL19082743 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL219189 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL219188 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL22433392 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL20636193 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL6157512 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | claimed |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-12496282-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2025-08-14 | — | — | US | disclosed |
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2025-04-10 | — | — | US | disclosed |
| US-20240400584-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240366538-A1 | Hepatitis B Antiviral Agents | ENANTA PHARM INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2024-09-24 | — | — | US | disclosed |
| US-12011425-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-7507736-B2 | Indol-2-yl-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090076002-A1 | NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-03-19 | — | — | US | disclosed |
| EP-1957493-A1 | 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | N.V. Organon (NL) | 2008-08-20 | — | — | EP | disclosed |
| US-20080188484-A1 | INDOL-2-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070185156-A1 | 8-Azabicyclo[3.2.1]octane derivatives | N.V. ORGANON (NL) | 2007-08-09 | — | — | US | disclosed |
| WO-2007063071-A1 | 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | N.V. ORGANON (NL) | 2007-06-07 | — | — | WO | disclosed |
| US-6051575-A | RESPIRATORY SYSTEM DISORDERS; SKIN DISORDERS; ANTIINFLAMMATORY AGENTS | SCHERING CORPORATION (US) | 2000-04-18 | — | — | US | disclosed |
| US-5968929-A | USEFUL IN THE TREATMENT OF CHRONIC AIRWAY DISEASES SUCH AS ASTHMA | SCHERING CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | CHRM2 4119/4885CHRM1 3159/4885CHRM3 4516/4885 |
| US-20040006135-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, HTR3A | CHRM2 421/4885CHRM1 397/4885CHRM3 164/4885 |
| US-20240400584-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | CHRM2 4750/4885CHRM1 4495/4885CHRM3 4238/4885 |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | CHRM2 1113/4885CHRM1 1153/4885CHRM3 1015/4885 |
| US-12011425-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | CHRM2 4838/4885CHRM1 4643/4885CHRM3 4810/4885 |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | CLIC1, HCCS, CNR1 | CHRM2 172/4885CHRM1 143/4885CHRM3 268/4885 |
| US-20080188484-A1 | INDOL-2-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HRH4, HRH3, HRH2 | CHRM2 35/4885CHRM1 20/4885CHRM3 44/4885 |
| US-20240366538-A1 | Hepatitis B Antiviral Agents | HAVCR2, PYGL, SLC10A1 | CHRM2 4838/4885CHRM1 4643/4885CHRM3 4810/4885 |
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | CHRM2 1374/4885CHRM1 1202/4885CHRM3 1494/4885 |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | CHRM2 4119/4885CHRM1 3159/4885CHRM3 4516/4885 |
| US-20090076002-A1 | NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | AADAT, PNMT, MCHR1 | CHRM2 66/4885CHRM1 33/4885CHRM3 18/4885 |
| US-12496282-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | CHRM2 4838/4885CHRM1 4643/4885CHRM3 4810/4885 |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | CBR1, CLIC1, RER1 | CHRM2 185/4885CHRM1 149/4885CHRM3 217/4885 |
| US-20070185156-A1 | 8-Azabicyclo[3.2.1]octane derivatives | SLC22A8, SLCO1B3, SLCO1B1 | CHRM2 1718/4885CHRM1 1961/4885CHRM3 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.